Please login to the form below

Not currently logged in


This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.

Generic Differentiation

Generic Differentiation

The former is evidenced, most recently, by the biosimilars piling in the moment Humira loses protection. ... And evolution predicts a fourth model, the ‘Frugal Followers’, that is not yet fully emerged but Samsung Bioepis looks like a contender to

Latest news

More from news
Approximately 125 fully matching, plus 254 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 11 fully matching, plus 52 partially matching documents found.

Latest appointments

  • Ashfield, Health Unlimited and Ashley Communications add to their teams Ashfield, Health Unlimited and Ashley Communications add to their teams

    Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK diabetes team.

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop

  • PharmaLex appoints Zabin Younes as associate director PharmaLex appoints Zabin Younes as associate director

    She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years, Younes’

  • GW Pharmaceuticals strengthens research and development team GW Pharmaceuticals strengthens research and development team

    Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and

  • Sandoz UK promotes Tim de Gavre to country head Sandoz UK promotes Tim de Gavre to country head

    Novartis’ generics and biosimilar division Sandoz has appointed Tim de Gavre as its new country head for the UK. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs, and helps the NHS

More from appointments
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest from PMHub

  • NHS medicines optimisation milestone

    Tackling variations in the uptake of biosimilars locally has been a key focus for RMOCs. ... The best biologics agenda and pharma. In line with the Commissioning Framework for Biological Medicines, NHS England, NHS Improvement and NHS Clinical

  • New local NHS models help to deliver integrated care

    A classic example of the way in which this can be achieved can be seen in the development of some biosimilar medicines, which are moving away from infusion to subcutaneous injections

  • OPEN Access Consulting

    What OPEN Access Consulting do:. We have unrivalled experience in the delivery of market access programmes from early phase insights to generic/biosimilar strategies. ... High-cost medicines. Rare diseases. Long-term conditions. Generic and biosimilar

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. . ... Biosimilar Cost-Savings in Reality

  • Ashfield launches new commercial model to improve ROI

    The transformational new model helps pharmaceutical companies optimise their investment in light of margin pressure, loss of exclusivity, new product data and new market entrants including biosimilars.

More from PMHub
Approximately 13 fully matching, plus 23 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...